Get the Stockscreener App
6.76
3.98%
-0.28
After Hours:
6.85
0.09
+1.33%
Sagimet Biosciences Inc stock is traded at $6.76, with a volume of 376.44K.
It is down -3.98% in the last 24 hours and down -29.21% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$7.04
Open:
$7.08
24h Volume:
376.44K
Relative Volume:
0.34
Market Cap:
$209.57M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-5.6998
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
-4.92%
1M Performance:
-29.21%
6M Performance:
+92.59%
1Y Performance:
+98.82%
1-Day Range:
$6.75
$7.1604
1-Week Range:
$6.75
$7.35
52-Week Range:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
6.76 | 231.88M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Initiated | Wedbush | Outperform |
| Aug-07-25 | Resumed | H.C. Wainwright | Buy |
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Can volume confirm reversal in Sagimet Biosciences Inc.July 2025 Retail & Capital Efficiency Focused Ideas - Newser
Forecasting Sagimet Biosciences Inc. price range with options data2025 Market Sentiment & Reliable Intraday Trade Alerts - Newser
What’s the recovery path for long term holders of Sagimet Biosciences Inc.Earnings Miss & Consistent Profit Trading Strategies - Newser
Does Sagimet Biosciences Inc. qualify in momentum factor screeningWeekly Loss Report & Community Verified Swing Trade Signals - Newser
Real time social sentiment graph for Sagimet Biosciences Inc.Global Markets & Risk Controlled Daily Plans - Newser
How to track smart money flows in Sagimet Biosciences Inc.Quarterly Profit Summary & Daily Volume Surge Signals - Newser
Will Sagimet Biosciences Inc. stock go up soonMarket Growth Report & Expert Approved Momentum Trade Ideas - Newser
Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Alyeska Investment Group L.P. Trims Stock Position in Sagimet Biosciences Inc. $SGMT - MarketBeat
Sagimet Biosciences to Present at the 9th Annual MASH Drug Development Summit on Innovations in Metabolic Dysfunction and Fibrosis Treatment - Quiver Quantitative
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit - GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit - GlobeNewswire Inc.
Price action breakdown for Sagimet Biosciences Inc.July 2025 Big Picture & Smart Allocation Stock Tips - Newser
Will Sagimet Biosciences Inc. Benefit From Broader Market BounceJuly 2025 Setups & Daily Entry Point Trade Alerts - beatles.ru
Can Sagimet Biosciences Inc. continue delivering strong returnsJuly 2025 Closing Moves & Comprehensive Market Scan Reports - beatles.ru
Is Sagimet Biosciences Inc. attractive at current valuation2025 Volume Leaders & Weekly Watchlist of Top Performers - خودرو بانک
Sagimet Biosciences shares fall 1.55% after-hours following presentation at Cantor Global Healthcare Conference. - AInvest
What indicators show strength in Sagimet Biosciences Inc.July 2025 Analyst Calls & Safe Capital Growth Plans - Newser
Sagimet Biosciences’ Strategic Positioning in the Biotech Sector - AInvest
Sagimet Biosciences Presents at Cantor Global Healthcare Conference 2025 - AInvest
Transcript : Sagimet Biosciences Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 01 - MarketScreener
Sagimet Biosciences Inc.’s volatility index tracking explainedWeekly Trade Report & Smart Investment Allocation Tips - Newser
Is Sagimet Biosciences Inc. stock bottoming outGlobal Markets & Risk Adjusted Swing Trade Ideas - Newser
Is Sagimet Biosciences Inc. a strong candidate for buy and hold2025 Retail Activity & Smart Allocation Stock Tips - خودرو بانک
News impact scoring models applied to Sagimet Biosciences Inc.Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Earnings visualization tools for Sagimet Biosciences Inc.Day Trade & Real-Time Stock Price Movement Reports - Newser
Real time scanner hits for Sagimet Biosciences Inc. explainedJuly 2025 Trends & Weekly Return Optimization Alerts - Newser
How high can Sagimet Biosciences Inc. stock price go in 20252025 Market Sentiment & Free Community Supported Trade Ideas - Newser
What is the Moat Score of Sagimet Biosciences Inc.2025 AllTime Highs & Expert Verified Movement Alerts - خودرو بانک
Technical Bounce Expected in Sagimet Biosciences Inc. Next Week2025 Performance Recap & Stepwise Entry and Exit Trade Signals - beatles.ru
Applying sector rotation models to Sagimet Biosciences Inc.July 2025 PostEarnings & Pattern Based Trade Signal System - Newser
Is Sagimet Biosciences Inc. gaining market shareTrend Reversal & Free High Accuracy Swing Entry Alerts - خودرو بانک
How to build a dashboard for Sagimet Biosciences Inc. stockMarket Sentiment Report & Technical Pattern Alert System - Newser
How high can Sagimet Biosciences Inc. stock go2025 Market Overview & Daily Risk Controlled Trade Plans - Newser
Is Sagimet Biosciences Inc. stock a buy or sellMarket Risk Analysis & Reliable Price Breakout Alerts - خودرو بانک
Can Sagimet Biosciences Inc. deliver consistent dividendsJuly 2025 Market Mood & Reliable Intraday Trade Plans - خودرو بانک
Is Sagimet Biosciences Inc. meeting your algorithmic filter criteriaLong Setup & Real-Time Chart Breakout Alerts - Newser
Is Sagimet Biosciences Inc. stock a good pick for beginnersJuly 2025 Analyst Calls & Real-Time Volume Analysis Alerts - خودرو بانک
Sagimet Biosciences Inc. stock momentum explained2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - Newser
How to monitor Sagimet Biosciences Inc. with trend dashboardsAnalyst Upgrade & Breakout Confirmation Alerts - Newser
Using data filters to optimize entry into Sagimet Biosciences Inc.Quarterly Growth Report & Free Safe Capital Growth Stock Tips - Newser
Tools to monitor Sagimet Biosciences Inc. recovery probabilityWeekly Trade Report & Community Consensus Picks - Newser
Momentum Screeners Rank Sagimet Biosciences Inc. in Top 5 TodayJuly 2025 Pullbacks & Advanced Technical Analysis Signals - beatles.ru
Sagimet Biosciences: Strong Pipeline Progress, Funding Overhang Keeps Stock at Hold - AInvest
Sagimet Biosciences: Strong Denifanstat Pipeline Progress, Funding Overhang Keeps Stock At Hold - Seeking Alpha
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):